immatics biotechnologies GmbH
NASDAQ Capital MarketTotal Valuation
immatics biotechnologies GmbH carries a market capitalization of 72,922.00, placing it among publicly traded companies globally. Its enterprise value stands at -438.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 72,922.00 |
| Enterprise Value | -438.49M |
Share Statistics
immatics biotechnologies GmbH currently has 136.67M shares outstanding.
| Shares Outstanding | 136.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
immatics biotechnologies GmbH maintains a current ratio of 8.78, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.31, indicating elevated leverage, while an interest coverage ratio of -220.76 demonstrates limited ability to service its debt obligations.
| Current Ratio | 8.78 |
| Quick Ratio | 8.30 |
| Debt / Equity | 3.31 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | -220.76 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -36.19 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -942,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
immatics biotechnologies GmbH's stock has declined approximately -99.98013% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.98013% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.71 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -200.67M, while operating income came in at -212.70M.
| Revenue | 37.30M |
| Gross Profit | N/A |
| Operating Income | -212.70M |
| Pretax Income | -215.35M |
| Net Income | -214.40M |
| EBITDA | -200.67M |
| EBIT | -212.70M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
immatics biotechnologies GmbH holds 453.57M in cash and equivalents against 15.08M in total debt, resulting in a net debt position of -301.33M. Total book value stands at -842.43M, with working capital of 429.59M providing operational flexibility.
| Cash & Cash Equivalents | 453.57M |
| Total Debt | 15.08M |
| Net Debt | -301.33M |
| Equity (Book Value) | -842.43M |
| Book Value Per Share | N/A |
| Working Capital | 429.59M |
Cash Flow
immatics biotechnologies GmbH produced -184.46M in operating cash flow over the past twelve months.
| Operating Cash Flow | -184.46M |
| Capital Expenditures | -4.43M |
| Free Cash Flow | -188.90M |
| FCF Per Share | N/A |
Margins
immatics biotechnologies GmbH operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -570.30 and net profit margin of -574.86 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -570.30 |
| Pretax Margin | -577.38 |
| Profit Margin | -574.86 |
| EBITDA Margin | -538.03 |
Scores
immatics biotechnologies GmbH posts an Altman Z-Score of -2.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.46 |